JP2025503967A5 - - Google Patents

Info

Publication number
JP2025503967A5
JP2025503967A5 JP2024544442A JP2024544442A JP2025503967A5 JP 2025503967 A5 JP2025503967 A5 JP 2025503967A5 JP 2024544442 A JP2024544442 A JP 2024544442A JP 2024544442 A JP2024544442 A JP 2024544442A JP 2025503967 A5 JP2025503967 A5 JP 2025503967A5
Authority
JP
Japan
Prior art keywords
sequence
receptor
item
immune cell
cell according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503967A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/011698 external-priority patent/WO2023147019A2/en
Publication of JP2025503967A publication Critical patent/JP2025503967A/ja
Publication of JP2025503967A5 publication Critical patent/JP2025503967A5/ja
Pending legal-status Critical Current

Links

JP2024544442A 2022-01-28 2023-01-27 メソテリン陽性がんを処置するための組成物及び方法 Pending JP2025503967A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263304409P 2022-01-28 2022-01-28
US63/304,409 2022-01-28
PCT/US2023/011698 WO2023147019A2 (en) 2022-01-28 2023-01-27 Compositions and methods for treating mesothelin positive cancers

Publications (2)

Publication Number Publication Date
JP2025503967A JP2025503967A (ja) 2025-02-06
JP2025503967A5 true JP2025503967A5 (cg-RX-API-DMAC10.html) 2026-01-30

Family

ID=87472570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544442A Pending JP2025503967A (ja) 2022-01-28 2023-01-27 メソテリン陽性がんを処置するための組成物及び方法

Country Status (10)

Country Link
US (1) US20250269027A1 (cg-RX-API-DMAC10.html)
EP (1) EP4469559A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025503967A (cg-RX-API-DMAC10.html)
KR (1) KR20240155391A (cg-RX-API-DMAC10.html)
CN (1) CN119403921A (cg-RX-API-DMAC10.html)
AU (1) AU2023213691A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243381A1 (cg-RX-API-DMAC10.html)
IL (1) IL314114A (cg-RX-API-DMAC10.html)
MX (1) MX2024009338A (cg-RX-API-DMAC10.html)
WO (1) WO2023147019A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026527004A (ja) * 2023-08-02 2026-08-10 エー2 バイオセラピューティクス, インコーポレイテッド Hla-a*03の発現の喪失を伴うがんを治療するための組成物および方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109504696A (zh) * 2017-09-15 2019-03-22 上海恒润达生生物科技有限公司 靶向人源化mesothelin的嵌合抗原受体的方法和用途
BR112021006100A2 (pt) * 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
WO2020190483A1 (en) * 2019-03-15 2020-09-24 Rutgers, The State University Of New Jersey Cd147 chimeric antigen receptors and methods of use
SG11202112676VA (en) * 2019-05-16 2021-12-30 Memorial Sloan Kettering Cancer Center Mesothelin cars and uses thereof
EP4010377A4 (en) * 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS
WO2021119489A1 (en) * 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
WO2022040454A1 (en) * 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers

Similar Documents

Publication Publication Date Title
JP2023538115A5 (cg-RX-API-DMAC10.html)
IL300500A (en) Preparations and methods for the treatment of mesothelin positive cancer
KR102470294B1 (ko) 암을 치료하기 위한 항-pd1 항체 및 방사선의 조합
TWI454260B (zh) 包含專一性辨識cd38之抗體及黴法蘭(melphalan)之抗腫瘤組合
JP2023538116A5 (cg-RX-API-DMAC10.html)
TWI436770B (zh) 包含專一性辨識cd38之抗體及阿糖胞苷(cytarabine)之抗腫瘤組合
JP2023538114A5 (cg-RX-API-DMAC10.html)
JP2020503273A5 (cg-RX-API-DMAC10.html)
JP2024527606A5 (cg-RX-API-DMAC10.html)
CA2947471A1 (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
IL300497A (en) Compositions and methods for treating CEACAM-positive cancer
JP7704748B2 (ja) 逐次抗cd19治療
JP6578604B2 (ja) 固形がんの治療剤
CA3136568A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
JP2022528030A5 (cg-RX-API-DMAC10.html)
IL300629A (en) Preparations and methods for the treatment of EGFR positive cancer
JP2021511372A5 (cg-RX-API-DMAC10.html)
JP2021534784A5 (cg-RX-API-DMAC10.html)
JP2021512637A5 (cg-RX-API-DMAC10.html)
US20250215087A1 (en) Combination therapy of kras inhibitor and treg depleting agent
Danhof et al. CARs and other T cell therapies for MM: the clinical experience
Pan et al. Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement
WO2017205216A1 (en) Combination of pembrolizumab and abemaciclib for the treatment of cancer
WO2019053613A2 (en) POLY THERAPY FOR THE TREATMENT OF CANCER
JP2023554422A (ja) がんの治療のための多重特異性抗体